Search results for "Coagulative necrosis"

showing 2 items of 12 documents

Electrospun PHEA-PLA/PCL Scaffold for Vascular Regeneration: A Preliminary in Vivo Evaluation

2017

Abstract Background There is increasing interest in the development of vessel substitutes, and many studies are currently focusing on the development of biodegradable scaffolds capable of fostering vascular regeneration. We tested a new biocompatible and biodegradable material with mechanical properties similar to those of blood vessels. Methods The material used comprises a mixture of α,β-poly(N-2-hydroxyethyl)- d,l -aspartamide (PHEA) and polylactic acid (PLA), combined with polycaprolactone (PCL) by means of electrospinning technique. Low-molecular-weight heparin was also linked to the copolymer. A tubular PHEA-PLA/PCL sample was used to create an arteriovenous fistula in a pig model wit…

ScaffoldMaterials scienceBiocompatibilityPolymersSwinePolyesters0206 medical engineering02 engineering and technologySettore MED/22 - Chirurgia VascolareNeovascularizationchemistry.chemical_compoundPolylactic acidBlood vessel prosthesismedicineAnimalsTransplantationRegeneration (biology)Bioabsorbable scaffold Bioengineered vascular scaffold Experimental surgery021001 nanoscience & nanotechnology020601 biomedical engineeringBlood Vessel ProsthesisSettore MED/18 - Chirurgia GeneraleCoagulative necrosischemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPolycaprolactoneSurgerymedicine.symptomPeptides0210 nano-technologyBiomedical engineeringTransplantation Proceedings
researchProduct

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

2001

Interleukin 12 (IL-12) has potential efficacy in malignant, infectious and allergic diseases. Its side-effects include activation of coagulation and fibrinolysis, as documented in chimpanzees. We assessed the coagulative and fibrinolytic response in 18 patients with renal cell carcinoma after subcutaneous injection of 0.5 microg/kg recombinant human IL-12. IL-12 induced a fibrinolytic response in 17 patients (94%): plasmin-alpha2-anti-plasmin complexes (PAPc) increased from 11.8 +/- 6.6 nmol/l (mean +/- SD) to a maximum of 18.8 +/- 7.4 nmol/l at 72 h. Baseline levels of tissue plasminogen activator (tPA) and plasminogen-activator inhibitor-I (PAI) were elevated in eight and 14 patients resp…

medicine.medical_specialtyNecrosisbusiness.industrymedicine.medical_treatmentHematologyTissue plasminogen activatorSubcutaneous injectionEndocrinologyCoagulative necrosisCoagulationInternal medicineHemostasisFibrinolysismedicineInterleukin 12medicine.symptombusinessmedicine.drugBritish Journal of Haematology
researchProduct